Denali Therapeutics Inc. - Common Stock — Cash Flow (NASDAQ:DNLI) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities 416.15 M-211.39 M-244.72 M-357.99 M-347.69 M-412.6 M -412.34 M Cash from investing activities -623.21 M-21.63 M-141.39 M249.31 M-88.76 M255.28 M 330.99 M Cash from financing activities 634.75 M19.35 M310.67 M17.82 M484.3 M189.22 M 412.02 M Free cash flow 416.15 M-211.39 M-244.72 M-357.99 M-347.69 M-422.1 M -419.23 M

News

Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?

Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data

Leqembi Isn’t Enough To Save Biogen Momentum (NASDAQ:BIIB)

Stocks Settle Higher on Iran Peace Hopes and Tech Strength

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

Stocks Climb on US-Iran Peace Hopes and Strength in Chipmakers

Stocks Supported by US-Iran Peace Deal Optimism

DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects

Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform

DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?

Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying.

Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome - Slideshow (NASDAQ:DNLI) 2026-03-27